All three strengths of the competitor branded as Wixela Inhub will be offered at a wholesale cost of 70% less than Advair Diskus and 67% less than GSK’s authorised generic version, which ...
Even though Advair’s main patent expired in 2010 and ... Mylan obtained approval to market the generic dubbed Wixela Inhub in three strengths: fluticasone propionate 100 mcg/salmeterol 50 ...
Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback